Envoy Medical stock analysis
Want to see COCH full AI Analyst Report?
Envoy Medical (COCH) Stock Price & Analysis
COCH Stock Chart & Stats
- Day’s Range
- $6.71 - $7.13
- 52-Week Range
- $3.62 - $9.53
- Previous Close
- $6.87
- Volume
- N/A
- Average Volume (3M)
- 27.48K
- Market Cap
- $53.20M
- Enterprise Value
- $57.28M
- Total Cash (Recent Filing)
- $14.57M
- Total Debt (Recent Filing)
- $777.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.29
- Next Earnings
- Apr 06, 2027 (Est.)
- EPS Estimate
- -0.65
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation
Acclaim’s fully implanted design could address usability and lifestyle limitations associated with external hearing components. Its differentiated architecture, rechargeable battery, and compatibility with earbuds may support clinician and patient interest if clinical and regulatory milestones are achieved.
Clinical And Regulatory Progress
Full pivotal-trial enrollment and progress on modular PMA submissions represent meaningful execution milestones for an investigational device. Continued progress reduces development uncertainty and creates a clearer path toward potential commercialization, although FDA review and final data remain outstanding.
Addressable Market
The stated market opportunity provides substantial room for long-term adoption if Acclaim receives approval and gains clinical acceptance. Low penetration among estimated adult candidates suggests the category could expand materially, giving Envoy a large demand pool to pursue beyond its current small revenue base.
Bears Say
Weak Revenue And Profitability
Envoy currently generates very little revenue relative to its development cost structure, and negative gross profit shows that existing sales do not yet cover product costs. The resulting losses limit internally funded growth and leave successful commercialization essential to improving earnings power.
Cash Burn And Capital Weakness
Persistent cash consumption alongside negative shareholders’ equity indicates limited financial flexibility for an early-stage medical-device company. Funding the clinical program, regulatory work, hiring, and facility expansion may require continued external capital, potentially constraining strategic choices.
Approval And Commercialization Risk
Acclaim cannot yet support broad commercial adoption because FDA approval has not been granted and the full clinical database remains incomplete. Delayed approval or additional regulatory requirements could postpone revenue scale-up while Envoy continues funding development and commercialization preparations.
Envoy Medical News
COCH FAQ
What was Envoy Medical’s price range in the past 12 months?
What is Envoy Medical’s market cap?
When is Envoy Medical’s upcoming earnings report date?
How were Envoy Medical’s earnings last quarter?
Is Envoy Medical overvalued?
Does Envoy Medical pay dividends?
What is Envoy Medical’s EPS estimate?
How many shares outstanding does Envoy Medical have?
What happened to Envoy Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Envoy Medical?
What is the TipRanks Smart Score and how is it calculated?
Envoy Medical Stock Smart Score
Company Description
Envoy Medical
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Brent T. Lucas
- Employees
- 43
- Website
- www.envoymedical.com
- Address
- 4875 White Bear Parkway, White Bear Lake, MN, 55110, US
Envoy Medical (COCH) Earnings & Revenues
COCH Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, characterized by full enrollment of the pivotal trial, encouraging stage 1 clinical results, progress on the modular PMA submission, a substantial estimated market opportunity, and preparations for commercialization. The company still faces meaningful challenges, including its investigational regulatory status, incomplete clinical data, a programming learning curve, limited current revenue, continued net losses, and the need to expand manufacturing capacity.
View all COCH earnings summariesCOCH Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 6 | 6 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 7 | 0 | 5 |










